Phenaros Pharmaceuticals

Phenaros Pharmaceuticals is a Swedish spin-off from Uppsala University, focused on transforming drug discovery through a cutting-edge AI-first platform. Specializing in phenomics, the company combines large-scale cell morphological profiling with AI and automation to accelerate the identification and repurposing of drugs, particularly for rare diseases. Phenaros’ approach utilizes Cell Painting, a method of detailed, high-content imaging of cells, to capture unique cellular signatures. These profiles enable predictions of a drug’s mechanism of action, target identification, and cellular toxicity. The company’s platform is powered by a robust AI engine that processes vast amounts of data generated by automated experiments. This AI-driven methodology significantly enhances the speed, efficiency, and safety of the drug discovery process, bypassing the traditional, slow-paced methods. In addition to its own drug discovery pipeline, Phenaros collaborates with pharma and biotech companies, providing them with access to its innovative discovery platform. Phenaros is committed to automating data collection and leveraging it as a key asset to continually improve its AI algorithms. Their unique, integrated approach leads to faster and more efficient drug development, helping bring treatments to market with fewer resources. By focusing on rare diseases, Phenaros addresses a significant unmet medical need while also aiming to transform the way drug discovery is conducted globally.